A Phase 3 interventional study of Dabigatran and Apixaban in Stroke, Ischemic, sponsored by University of Zurich. Recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-16.
Sponsored by University of Zurich · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Ischemic Stroke with a site in Switzerland — 27 open to participants now, 33 under way, 3 of them phase 3. Ischemic Stroke · Switzerland.
Among the 86 studies in Ischemic Stroke with a site in Switzerland, this one is the 15th largest by planned enrollment of the 42 interventional ones that give a count, is one of 12 that started in 2019, is one of 16 in phase 3, reaches primary completion later than 4 of the 32 other live ones, and was the 38th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →27 of the 86 studies in Ischemic Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Penumbra Inc. · Sites in Switzerland, Australia, Canada and 2 more countries
Ages 18–80
Emmanuel Carrera · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 620 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 487 across the 42 interventional studies, 481 across the 44 observational. Of the 45 that completed or were terminated, 14 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 86 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 9 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Ischemic Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06394180University Hospital, Basel, SwitzerlandPeRforation EVents During ENdovascular Therapy for Acute Ischemic Stroke | 2026-12 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04862507Universitätsklinikum Hamburg-EppendorfImproving Low ASPECTS Stroke Thrombectomy | 2027-01-01 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
| NCT04075084Biotronik SE & Co. KGObservation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) | 2027-05-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 86 studies in Ischemic Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present trial is addressing the question if a biologically distinct subgroup of ischemic stroke patients without known atrial fibrillation at admission, selected by a cut-off level of MRproANP concentration, which represents a underlying increased risk of cardiac thrombogenicity, benefits from direct oral anticoagulation (DOAC) within 7 days of symptom onset versus standard of care (antiplatelet) as preventive treatment.
Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible patients will be randomly assigned to either the standard of care (control) or the experimental (direct start with DOAC) arm with a ratio of 1:1. Each study participant will be observed during a follow up period within one year after index stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Direct oral anticoagulants
Drug: Dabigatran · Drug: Apixaban · Drug: Edoxaban
SOC therapy with antiplatelets until study completion or until detection of AF. After detection of AF treatment with DOAC becomes SOC.
Drug: Aspirin · Drug: Clopidogrel
150mg 2x/d
Also known as: Pradaxa
5mg 2x/d
Also known as: Eliquis
60mg 1x/d
Also known as: Lixiana
100mg 1x/d
Also known as: Aspirin cardio
75mg 1x/d
Recurrent stroke of any type
The primary outcome measure is the time to any recurrent stroke (ischemic, hemorrhagic, unspecified, or fatal stroke)
Time frame: within one year after index stroke
Composite of major bleeding, recurrent stroke and/or vascular death
Composite of major bleeding, recurrent stroke and/or vascular death (whichever occurs first)
Time frame: within one year after index stroke
Major bleeding, recurrent stroke and/or vascular death as single components
Each single component of the composite in outcome 2 (major bleeding, recurrent stroke and/or vascular death)
Time frame: within one year after index stroke
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Jan 2025, 61 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 61 months is above that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabigatran · Apixaban · Edoxaban